PubMed:9643569 JSON TXT

Annnotations TAB JSON ListView MergeView

DisGeNET

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":272,"end":279},"obj":"gene:84106"},{"id":"T1","span":{"begin":186,"end":215},"obj":"disease:C0242596"},{"id":"T2","span":{"begin":272,"end":279},"obj":"gene:84106"},{"id":"T3","span":{"begin":234,"end":256},"obj":"disease:C0023467"},{"id":"T4","span":{"begin":272,"end":279},"obj":"gene:84106"},{"id":"T5","span":{"begin":258,"end":261},"obj":"disease:C0023467"},{"id":"T6","span":{"begin":289,"end":293},"obj":"gene:861"},{"id":"T7","span":{"begin":186,"end":215},"obj":"disease:C0242596"},{"id":"T8","span":{"begin":289,"end":293},"obj":"gene:861"},{"id":"T9","span":{"begin":234,"end":256},"obj":"disease:C0023467"},{"id":"T10","span":{"begin":294,"end":297},"obj":"gene:862"},{"id":"T11","span":{"begin":186,"end":215},"obj":"disease:C0242596"},{"id":"T12","span":{"begin":294,"end":297},"obj":"gene:862"},{"id":"T13","span":{"begin":234,"end":256},"obj":"disease:C0023467"},{"id":"T14","span":{"begin":294,"end":297},"obj":"gene:862"},{"id":"T15","span":{"begin":258,"end":261},"obj":"disease:C0023467"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"},{"id":"R7","pred":"associated_with","subj":"T12","obj":"T13"},{"id":"R8","pred":"associated_with","subj":"T14","obj":"T15"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.\nHere we studied minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic analysis of lymphocyte subsets involved in antitumor immunity. Eight patients in long-term (LT; 3 to 15 years) and 15 patients in short-term (ST; up to 3 years) remission were studied. Using the reverse transcription-polymerase chain reaction (RT) assay, the limit of detection was 10(-5) to 10(-6) for PML/RAR alpha transcript and 10(-4) to 10(-5) for the AML1/ETO transcript. Simultaneously, T lymphocyte subsets and NK cells from the peripheral blood (PB) and bone marrow (BM) were investigated by flow cytometric analysis. Four of the eight patients in LT and 7 of the 15 patients in ST remission were MRD-positive. Although all MRD-positive patients in LT remission are still until now event-free, 3 of the 7 MRD-positive (MRD+) patients in ST remission soon relapsed. The total populations of CD4+, CD8+ and CD56+ [possible T-cell and natural killer (T/NK) populations] in the BM of ST patients and MRD+/LT patients were significantly (p \u003c .01) low. The CD8+ CD28+ population showed the same tendency (p \u003c .01-.02). The T/NK subsets in the BM of MRD-negative (MRD-) LT (MRD-/LT) patients showed similar numbers of cells as normal volunteers. Basically, the total percentage of the CD4+, CD8+ and CD56+ cell populations in the BM was increased and in the following order: MRD-/LT patients, normal volunteers, MRD+/LT patients and MRD+ or -/ST patients. The percentages of the T/NK-cell subsets in the PB were not significantly different among these groups. Thus, the difference of the possible T/NK-cell phenotype in the BM may strongly influence clinical and molecular remission. These results still remain to be confirmed by further studies of the functional anti-tumor immunity of T/NK cells of AML in remission."}

jnlpba-st-training

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":60,"end":90},"obj":"RNA"},{"id":"T2","span":{"begin":118,"end":153},"obj":"cell_type"},{"id":"T3","span":{"begin":272,"end":285},"obj":"protein"},{"id":"T4","span":{"begin":289,"end":297},"obj":"protein"},{"id":"T5","span":{"begin":336,"end":354},"obj":"cell_type"},{"id":"T6","span":{"begin":627,"end":651},"obj":"RNA"},{"id":"T7","span":{"begin":681,"end":700},"obj":"RNA"},{"id":"T8","span":{"begin":718,"end":738},"obj":"cell_type"},{"id":"T9","span":{"begin":743,"end":751},"obj":"cell_type"},{"id":"T10","span":{"begin":1123,"end":1126},"obj":"protein"},{"id":"T11","span":{"begin":1129,"end":1132},"obj":"protein"},{"id":"T12","span":{"begin":1138,"end":1142},"obj":"protein"},{"id":"T13","span":{"begin":1154,"end":1160},"obj":"cell_type"},{"id":"T14","span":{"begin":1165,"end":1179},"obj":"cell_type"},{"id":"T15","span":{"begin":1181,"end":1185},"obj":"cell_type"},{"id":"T16","span":{"begin":1284,"end":1287},"obj":"protein"},{"id":"T17","span":{"begin":1289,"end":1293},"obj":"protein"},{"id":"T18","span":{"begin":1350,"end":1362},"obj":"cell_type"},{"id":"T19","span":{"begin":1511,"end":1548},"obj":"cell_type"},{"id":"T20","span":{"begin":1705,"end":1722},"obj":"cell_type"},{"id":"T21","span":{"begin":1823,"end":1832},"obj":"cell_type"},{"id":"T22","span":{"begin":2013,"end":2023},"obj":"cell_type"}],"text":"Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.\nHere we studied minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic analysis of lymphocyte subsets involved in antitumor immunity. Eight patients in long-term (LT; 3 to 15 years) and 15 patients in short-term (ST; up to 3 years) remission were studied. Using the reverse transcription-polymerase chain reaction (RT) assay, the limit of detection was 10(-5) to 10(-6) for PML/RAR alpha transcript and 10(-4) to 10(-5) for the AML1/ETO transcript. Simultaneously, T lymphocyte subsets and NK cells from the peripheral blood (PB) and bone marrow (BM) were investigated by flow cytometric analysis. Four of the eight patients in LT and 7 of the 15 patients in ST remission were MRD-positive. Although all MRD-positive patients in LT remission are still until now event-free, 3 of the 7 MRD-positive (MRD+) patients in ST remission soon relapsed. The total populations of CD4+, CD8+ and CD56+ [possible T-cell and natural killer (T/NK) populations] in the BM of ST patients and MRD+/LT patients were significantly (p \u003c .01) low. The CD8+ CD28+ population showed the same tendency (p \u003c .01-.02). The T/NK subsets in the BM of MRD-negative (MRD-) LT (MRD-/LT) patients showed similar numbers of cells as normal volunteers. Basically, the total percentage of the CD4+, CD8+ and CD56+ cell populations in the BM was increased and in the following order: MRD-/LT patients, normal volunteers, MRD+/LT patients and MRD+ or -/ST patients. The percentages of the T/NK-cell subsets in the PB were not significantly different among these groups. Thus, the difference of the possible T/NK-cell phenotype in the BM may strongly influence clinical and molecular remission. These results still remain to be confirmed by further studies of the functional anti-tumor immunity of T/NK cells of AML in remission."}

DisGeNET5_gene_disease

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"9643569-0#60#67#gene84106","span":{"begin":60,"end":67},"obj":"gene84106"},{"id":"9643569-0#82#85#gene862","span":{"begin":82,"end":85},"obj":"gene862"},{"id":"9643569-0#0#24#diseaseC0242596","span":{"begin":0,"end":24},"obj":"diseaseC0242596"},{"id":"9643569-0#28#54#diseaseC0023467","span":{"begin":28,"end":54},"obj":"diseaseC0023467"},{"id":"9643569-1#119#123#gene861","span":{"begin":289,"end":293},"obj":"gene861"},{"id":"9643569-1#124#127#gene862","span":{"begin":294,"end":297},"obj":"gene862"},{"id":"9643569-1#16#40#diseaseC0242596","span":{"begin":186,"end":210},"obj":"diseaseC0242596"}],"relations":[{"id":"60#67#gene841060#24#diseaseC0242596","pred":"associated_with","subj":"9643569-0#60#67#gene84106","obj":"9643569-0#0#24#diseaseC0242596"},{"id":"60#67#gene8410628#54#diseaseC0023467","pred":"associated_with","subj":"9643569-0#60#67#gene84106","obj":"9643569-0#28#54#diseaseC0023467"},{"id":"82#85#gene8620#24#diseaseC0242596","pred":"associated_with","subj":"9643569-0#82#85#gene862","obj":"9643569-0#0#24#diseaseC0242596"},{"id":"82#85#gene86228#54#diseaseC0023467","pred":"associated_with","subj":"9643569-0#82#85#gene862","obj":"9643569-0#28#54#diseaseC0023467"},{"id":"119#123#gene86116#40#diseaseC0242596","pred":"associated_with","subj":"9643569-1#119#123#gene861","obj":"9643569-1#16#40#diseaseC0242596"},{"id":"124#127#gene86216#40#diseaseC0242596","pred":"associated_with","subj":"9643569-1#124#127#gene862","obj":"9643569-1#16#40#diseaseC0242596"}],"text":"Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.\nHere we studied minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic analysis of lymphocyte subsets involved in antitumor immunity. Eight patients in long-term (LT; 3 to 15 years) and 15 patients in short-term (ST; up to 3 years) remission were studied. Using the reverse transcription-polymerase chain reaction (RT) assay, the limit of detection was 10(-5) to 10(-6) for PML/RAR alpha transcript and 10(-4) to 10(-5) for the AML1/ETO transcript. Simultaneously, T lymphocyte subsets and NK cells from the peripheral blood (PB) and bone marrow (BM) were investigated by flow cytometric analysis. Four of the eight patients in LT and 7 of the 15 patients in ST remission were MRD-positive. Although all MRD-positive patients in LT remission are still until now event-free, 3 of the 7 MRD-positive (MRD+) patients in ST remission soon relapsed. The total populations of CD4+, CD8+ and CD56+ [possible T-cell and natural killer (T/NK) populations] in the BM of ST patients and MRD+/LT patients were significantly (p \u003c .01) low. The CD8+ CD28+ population showed the same tendency (p \u003c .01-.02). The T/NK subsets in the BM of MRD-negative (MRD-) LT (MRD-/LT) patients showed similar numbers of cells as normal volunteers. Basically, the total percentage of the CD4+, CD8+ and CD56+ cell populations in the BM was increased and in the following order: MRD-/LT patients, normal volunteers, MRD+/LT patients and MRD+ or -/ST patients. The percentages of the T/NK-cell subsets in the PB were not significantly different among these groups. Thus, the difference of the possible T/NK-cell phenotype in the BM may strongly influence clinical and molecular remission. These results still remain to be confirmed by further studies of the functional anti-tumor immunity of T/NK cells of AML in remission."}

genia-medco-coref

{"project":"genia-medco-coref","denotations":[{"id":"C2","span":{"begin":28,"end":54},"obj":"NP"},{"id":"C1","span":{"begin":0,"end":54},"obj":"NP"},{"id":"C3","span":{"begin":118,"end":153},"obj":"NP"},{"id":"C4","span":{"begin":157,"end":168},"obj":"NP"},{"id":"C7","span":{"begin":234,"end":262},"obj":"NP"},{"id":"C6","span":{"begin":220,"end":262},"obj":"NP"},{"id":"C5","span":{"begin":186,"end":262},"obj":"NP"},{"id":"C8","span":{"begin":263,"end":266},"obj":"NP"},{"id":"C9","span":{"begin":336,"end":354},"obj":"NP"},{"id":"C10","span":{"begin":718,"end":738},"obj":"NP"},{"id":"C11","span":{"begin":757,"end":782},"obj":"NP"},{"id":"C12","span":{"begin":787,"end":803},"obj":"NP"},{"id":"C13","span":{"begin":1229,"end":1245},"obj":"NP"},{"id":"C14","span":{"begin":1552,"end":1558},"obj":"NP"},{"id":"C16","span":{"begin":1638,"end":1654},"obj":"NP"},{"id":"C15","span":{"begin":1601,"end":1680},"obj":"NP"},{"id":"C17","span":{"begin":1726,"end":1732},"obj":"NP"},{"id":"C18","span":{"begin":1772,"end":1784},"obj":"NP"},{"id":"C19","span":{"begin":1846,"end":1852},"obj":"NP"},{"id":"C21","span":{"begin":2027,"end":2030},"obj":"NP"},{"id":"C20","span":{"begin":2013,"end":2030},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-ident","subj":"C7","obj":"C2"},{"id":"R2","pred":"coref-ident","subj":"C5","obj":"C1"},{"id":"R3","pred":"coref-relat","subj":"C8","obj":"C6"},{"id":"R4","pred":"coref-ident","subj":"C10","obj":"C9"},{"id":"R5","pred":"coref-ident","subj":"C12","obj":"C4"},{"id":"R6","pred":"coref-ident","subj":"C14","obj":"C12"},{"id":"R7","pred":"coref-ident","subj":"C16","obj":"C13"},{"id":"R8","pred":"coref-ident","subj":"C17","obj":"C11"},{"id":"R9","pred":"coref-ident","subj":"C18","obj":"C15"},{"id":"R10","pred":"coref-ident","subj":"C19","obj":"C14"},{"id":"R11","pred":"coref-ident","subj":"C21","obj":"C7"},{"id":"R12","pred":"coref-ident","subj":"C20","obj":"C3"}],"text":"Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.\nHere we studied minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic analysis of lymphocyte subsets involved in antitumor immunity. Eight patients in long-term (LT; 3 to 15 years) and 15 patients in short-term (ST; up to 3 years) remission were studied. Using the reverse transcription-polymerase chain reaction (RT) assay, the limit of detection was 10(-5) to 10(-6) for PML/RAR alpha transcript and 10(-4) to 10(-5) for the AML1/ETO transcript. Simultaneously, T lymphocyte subsets and NK cells from the peripheral blood (PB) and bone marrow (BM) were investigated by flow cytometric analysis. Four of the eight patients in LT and 7 of the 15 patients in ST remission were MRD-positive. Although all MRD-positive patients in LT remission are still until now event-free, 3 of the 7 MRD-positive (MRD+) patients in ST remission soon relapsed. The total populations of CD4+, CD8+ and CD56+ [possible T-cell and natural killer (T/NK) populations] in the BM of ST patients and MRD+/LT patients were significantly (p \u003c .01) low. The CD8+ CD28+ population showed the same tendency (p \u003c .01-.02). The T/NK subsets in the BM of MRD-negative (MRD-) LT (MRD-/LT) patients showed similar numbers of cells as normal volunteers. Basically, the total percentage of the CD4+, CD8+ and CD56+ cell populations in the BM was increased and in the following order: MRD-/LT patients, normal volunteers, MRD+/LT patients and MRD+ or -/ST patients. The percentages of the T/NK-cell subsets in the PB were not significantly different among these groups. Thus, the difference of the possible T/NK-cell phenotype in the BM may strongly influence clinical and molecular remission. These results still remain to be confirmed by further studies of the functional anti-tumor immunity of T/NK cells of AML in remission."}

pubmed-sentences-benchmark

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":169},"obj":"Sentence"},{"id":"S2","span":{"begin":170,"end":386},"obj":"Sentence"},{"id":"S3","span":{"begin":387,"end":508},"obj":"Sentence"},{"id":"S4","span":{"begin":509,"end":701},"obj":"Sentence"},{"id":"S5","span":{"begin":702,"end":850},"obj":"Sentence"},{"id":"S6","span":{"begin":851,"end":943},"obj":"Sentence"},{"id":"S7","span":{"begin":944,"end":1097},"obj":"Sentence"},{"id":"S8","span":{"begin":1098,"end":1279},"obj":"Sentence"},{"id":"S9","span":{"begin":1280,"end":1345},"obj":"Sentence"},{"id":"S10","span":{"begin":1346,"end":1471},"obj":"Sentence"},{"id":"S11","span":{"begin":1472,"end":1681},"obj":"Sentence"},{"id":"S12","span":{"begin":1682,"end":1785},"obj":"Sentence"},{"id":"S13","span":{"begin":1786,"end":1909},"obj":"Sentence"},{"id":"S14","span":{"begin":1910,"end":2044},"obj":"Sentence"}],"text":"Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.\nHere we studied minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic analysis of lymphocyte subsets involved in antitumor immunity. Eight patients in long-term (LT; 3 to 15 years) and 15 patients in short-term (ST; up to 3 years) remission were studied. Using the reverse transcription-polymerase chain reaction (RT) assay, the limit of detection was 10(-5) to 10(-6) for PML/RAR alpha transcript and 10(-4) to 10(-5) for the AML1/ETO transcript. Simultaneously, T lymphocyte subsets and NK cells from the peripheral blood (PB) and bone marrow (BM) were investigated by flow cytometric analysis. Four of the eight patients in LT and 7 of the 15 patients in ST remission were MRD-positive. Although all MRD-positive patients in LT remission are still until now event-free, 3 of the 7 MRD-positive (MRD+) patients in ST remission soon relapsed. The total populations of CD4+, CD8+ and CD56+ [possible T-cell and natural killer (T/NK) populations] in the BM of ST patients and MRD+/LT patients were significantly (p \u003c .01) low. The CD8+ CD28+ population showed the same tendency (p \u003c .01-.02). The T/NK subsets in the BM of MRD-negative (MRD-) LT (MRD-/LT) patients showed similar numbers of cells as normal volunteers. Basically, the total percentage of the CD4+, CD8+ and CD56+ cell populations in the BM was increased and in the following order: MRD-/LT patients, normal volunteers, MRD+/LT patients and MRD+ or -/ST patients. The percentages of the T/NK-cell subsets in the PB were not significantly different among these groups. Thus, the difference of the possible T/NK-cell phenotype in the BM may strongly influence clinical and molecular remission. These results still remain to be confirmed by further studies of the functional anti-tumor immunity of T/NK cells of AML in remission."}

GENIAcorpus